Australian multicenter study of isolated limb infusion for melanoma

Isolated limb infusion (ILI) offers a less invasive alternative to isolated limb perfusion (ILP) for the treatment of locally advanced extremity melanoma. In Australia, ILI has essentially completely replaced ILP. The aim of this study was to collect and evaluate the results of ILI in an Australian multicenter setting

Safety and Efficacy of Isolated Limb Infusion Chemotherapy for Advanced Locoregional Melanoma in Elderly Patients: An Australian Multicenter Study

Background: Isolated limb infusion (ILI) offers a minimally invasive treatment option for locally advanced extremity melanoma. Objective: The aim of the current study was to evaluate the safety and efficacy of ILI in elderly patients in an Australian multicenter setting. Methods: The results of 316 first ILI procedures, performed between 1992 and 2008 in five Australian institutions, were identified and analyzed, with the main focus on elderly patients (≥75\ua0years of age). All institutions used the same protocol: melphalan was circulated in the isolated limb for 20–30\ua0min (±actinomycin D), and toxicity, responses, and survival were recorded. Results: Characteristics of patients aged ≥75\ua0years (n\ua0=\ua0148) were similar to those age